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A BS TR AC T
Background
A single dose of nevirapine during labor reduces perinatal transmission of human 
immunodeficiency virus type 1 (HIV-1) but often leads to viral nevirapine resistance 
mutations in mothers and infants.
Methods
We studied the response to nevirapine-based antiretroviral treatment among women 
and infants who had previously been randomly assigned to a single, peripartum dose 
of nevirapine or placebo in a trial in Botswana involving the prevention of the trans-
mission of HIV-1 from mother to child. All women were treated with antenatal zidovu-
dine. The primary end point for mothers and infants was virologic failure by the 
6-month visit after initiation of antiretroviral treatment, estimated within groups by 
the Kaplan–Meier method.
Results
Of 218 women who started antiretroviral treatment, 112 had received a single dose 
of nevirapine and 106 had received placebo. By the 6-month visit after the initiation 
of antiretroviral treatment, 5.0% of the women who had received placebo had viro-
logic failure, as compared with 18.4% of those who had received a single dose of 
nevirapine (P = 0.002). Among 60 women starting antiretroviral treatment within 
6 months after receiving placebo or a single dose of nevirapine, no women in the 
placebo group and 41.7% in the nevirapine group had virologic failure (P<0.001). 
In contrast, virologic failure rates did not differ significantly between the placebo 
group and the nevirapine group among 158 women starting antiretroviral treatment 
6 months or more post partum (7.8% and 12.0%, respectively; P = 0.39). Thirty in-
fants also began antiretroviral treatment (15 in the placebo group and 15 in the 
nevirapine group). Virologic failure by the 6-month visit occurred in significantly 
more infants who had received a single dose of nevirapine than in infants who had 
received placebo (P<0.001). Maternal and infant findings did not change qualita-
tively by 12 and 24 months after the initiation of antiretroviral treatment.
Conclusions
Women who received a single dose of nevirapine to prevent perinatal transmission 
of HIV-1 had higher rates of virologic failure with subsequent nevirapine-based anti-
retroviral therapy than did women without previous exposure to nevirapine. However, 
this applied only when nevirapine-based antiretroviral therapy was initiated within 
6 months after receipt of a single, peripartum dose of nevirapine. (ClinicalTrials.gov 
number, NCT00197587.)
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Nevirapine remains central to the prevention of mother-to-child transmis-sion of human immunodeficiency virus 
type 1 (HIV-1) and to combination antiretroviral 
treatment throughout much of the developing 
world.1,2 Nevirapine administered as one dose to 
the mother and one to the newborn reduces 
mother-to-child transmission of HIV-1 by 41 to 
47%,3,4 and well over 875,000 women and infants 
have received a single dose of nevirapine.5 A single 
dose of nevirapine is the cornerstone of the regi-
men recommended by the World Health Organiza-
tion (WHO) to prevent mother-to-child transmis-
sion among women without access to antiretroviral 
treatment and among those not meeting treat-
ment criteria.1 However, nevirapine resistance is 
detected (with the use of standard genotyping 
techniques) in 20 to 69% of women6-10 and 33 to 
87% of infants11,12 after exposure to a single, peri-
partum dose of nevirapine (less frequently among 
HIV-infected infants who also received a short 
course of zidovudine prophylaxis13). As compared 
with placebo, a previous single dose of nevirapine 
was associated with lower rates of virologic sup-
pression to less than 50 copies per milliliter (but 
was not associated with lower rates of suppres-
sion to less than 400 copies per milliliter) on sub-
sequent nevirapine-based antiretroviral treatment 
in Thailand, although this finding was not associ-
ated with the timing of the postpartum initiation 
of antiretroviral treatment.14 To our knowledge, 
infant response to nevirapine-based antiretroviral 
treatment after the administration of a single dose 
of nevirapine has not been described. We conduct-
ed a prospective observational study nested within 
a randomized clinical trial to assess the virologic 
responses of women and infants to nevirapine-
based antiretroviral treatment after previous ex-
posure to a single dose of nevirapine or placebo in 
the setting of a short course of zidovudine.
Me thods
Study Population and Monitoring
Between March 2001 and October 2003, a total of 
1200 pregnant women in Botswana who were in-
fected with HIV-1 underwent randomization dur-
ing the Mashi trial of the prevention of mother-
to-child transmission of HIV-1.10,15 We conducted 
an observational antiretroviral-treatment study 
within the randomized cohort of the parent Mashi 
trial. In the Mashi trial, women received a short 
course of zidovudine from 34 weeks’ gestation 
through delivery, and mother–infant pairs were 
randomly assigned to receive, double-blinded, a 
single dose of nevirapine or placebo (one maternal 
dose at the onset of labor, and one infant dose at 48 
to 72 hours after birth). Mothers and their infants 
were also randomly assigned to either 6 months 
of breast-feeding with zidovudine prophylaxis for 
the infants or formula-feeding with 1 month of 
zidovudine for the infants (zidovudine for the in-
fants was stopped if infants were diagnosed with 
HIV infection). On August 12, 2002, in response to 
external data, the Mashi trial was modified to pro-
vide a single dose of nevirapine to all infants.10
Combination antiretroviral treatment with ne-
virapine and zidovudine–lamivudine (Combivir, 
GlaxoSmithKline) was made available to all qual-
ifying participants in the Mashi trial starting in 
October 2002. Pregnant or postpartum women 
with CD4+ cell counts of less than 200 cells per 
cubic millimeter or an acquired immunodeficiency 
syndrome (AIDS)–defining illness or both quali-
fied for antiretroviral treatment, as did infants 
infected with HIV-1 who were younger than 12 
months, whose percentage of CD4+ lymphocytes 
(CD4+ percentage) was less than 25%, or who had 
symptoms related to HIV-1. Nelfinavir, stavudine, 
and didanosine were available in cases of drug 
toxicity or virologic failure. The Botswana Health 
Research Development Committee and the Har-
vard School of Public Health Human Subjects 
Committee approved the study. All women pro-
vided written informed consent.
All women who consented to participate and 
who started postpartum nevirapine-based anti-
retroviral treatment before October 2004 (allowing 
for at least 9 months of antiretroviral treatment) 
were included in this analysis. All HIV-infected 
infants who were born before the Mashi Study 
was modified in August 2002 and who started 
nevirapine-based antiretroviral treatment were 
also included.
Before the initiation of antiretroviral treatment 
and every 3 months thereafter, mothers and their 
infants underwent clinical and laboratory moni-
toring (CD4+ cell count, plasma HIV-1 RNA mea-
surements, hematologic studies, blood chemical 
studies, and liver-function tests), and education 
about and assessment of adherence to treatment. 
Additional monitoring for toxic effects occurred 
2 and 4 weeks after the start of antiretroviral 
treatment.
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Measurement of Plasma HIV-1 RNA
Plasma HIV-1 RNA was assessed with the use of 
the standard Amplicor HIV-1 Monitor, version 1.5 
(Roche Diagnostics), protocol (lower limit of de-
tection, 400 copies per milliliter). The Roche Am-
plicor HIV-1 Monitor UltraSensitive Method (ver-
sion 1.5) protocol was used for a subgroup of 
women who had HIV-1 RNA levels below the low-
er limit of detection with the standard test.
HIV-1 Genotyping
HIV-1 genotyping was performed on plasma sam-
ples with the use of the ViroSeq HIV-1 Genotyping 
System (Celera Diagnostics). Nevirapine resistance 
was defined by the presence of any of the follow-
ing mutations: 100I, 103N, 106A/M, 108I, 181C/I, 
188L/C/H, or 190A (i.e., a score on the resistance 
scale of more than 50, according to the Stanford 
University drug-resistance database as of April 
2006).16 Plasma samples obtained before antiretro-
viral treatment and at the time of virologic failure 
for women with virologic failure were tested.
Study End Points
The primary study end point for both women and 
infants was virologic failure by the 6-month visit. 
Virologic failure was defined as a confirmed plas-
ma HIV-1 RNA level of at least 400 copies per mil-
liliter at or after the 6-month visit after the initia-
tion of antiretroviral treatment, or a drop in the 
HIV-1 RNA level of less than 1 log at the 3-month 
visit with a detectable plasma HIV-1 RNA level at 
6 months. Secondary end points included virolog-
ic failure by 12 and 24 months after the initiation 
of antiretroviral treatment, virologic failure by early 
(within 6 months post partum) or late (6 months 
or more post partum) initiation of antiretroviral 
treatment, an HIV-1 RNA level of less than 400 
copies per milliliter at 6, 12, and 24 months after 
the initiation of antiretroviral treatment, and time 
to virologic failure (the rate of virologic failure 
during the entire follow-up period).
Statistical Analysis
Pretreatment laboratory-test measurements were 
obtained within 90 days before the start of anti-
retroviral treatment. Window periods for visits 
used the midpoint between consecutively sched-
uled visits at 3, 6, 12, 18, and 24 months. All men-
tions of time points after the initiation of antiret-
roviral treatment refer to the related visit window. 
We used the Kaplan–Meier method to estimate 
the rates of virologic failure by the end of the 6-, 
12-, and 24-month windows for visits for the pri-
mary and related secondary end points. Data from 
women who did not have virologic failure were 
censored at the time of the last measurement of 
the plasma HIV-1 RNA level. For analyses compar-
ing viral loads at specific times, we used Fisher’s 
exact test to compare binomial proportions on 
observed HIV-1 RNA measurements.
To assess whether differences in virologic fail-
ure that occurred in recipients of a single dose 
of nevirapine or placebo varied according to the 
timing of the initiation of antiretroviral treatment 
after the single dose, we tested for a statistical 
interaction, using Cox regression, with time from 
delivery to the initiation of antiretroviral treat-
ment as a continuous covariate. We also modeled 
the interaction term by dividing the cohort into 
prespecified subgroups according to the timing 
of the initiation of antiretroviral treatment (less 
than 6 months post partum vs. 6 months or more 
post partum). When an interaction was detected, 
separate analyses were performed according to 
subgroup. We assessed time to virologic failure 
using the Cox regression model, and we used the 
log-rank test to compare recipients of a single 
dose of nevirapine with recipients of placebo. Wil-
coxon rank-sum tests were used to compare the 
distribution of CD4+ cell counts (or changes from 
baseline) in recipients of a single dose of nevirap-
ine and recipients of placebo at each time point. 
Analyses are based on all data available through 
July 2005, and all reported P values are two-sided 
and not adjusted for multiple testing.
R esult s
Study Population
Antiretroviral treatment was initiated in 304 wom-
en in the Mashi trial by October 2004. An addi-
tional 20 women (6 who received a single dose of 
nevirapine and 14 who received placebo) died be-
fore starting antiretroviral treatment. Of those 
who began treatment, 71 started ante partum and 
consequently did not receive a single peripartum 
dose of nevirapine or placebo, 8 started non–nevir-
apine-based antiretroviral treatment, and 7 were 
lost to follow-up or died before consenting to par-
ticipate in the study. Therefore, 218 women are 
included in this analysis (112 previously random-
ly assigned to a single peripartum dose of nevirap-
ine and 106 to placebo) (Fig. 1).
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Maternal characteristics of the 218 women 
enrolled were similar between the two groups 
(Table 1). Sixty women started antiretroviral treat-
ment within 6 months after delivery, and 158 
started 6 months or more after delivery. Measure-
ments of plasma HIV-1 RNA levels taken at the 
6-month visit were available for 109 women who 
had received a single dose of nevirapine (97.3%) 
and for 96 who had received placebo (90.6%) 
(Fig. 1). Measurements of HIV-1 RNA levels at 12 
months were available for 94 women in the nevir-
apine group (87.0%) and 88 women in the pla-
cebo group (88.9%).
The primary end point of virologic failure by 
6 months after the initiation of antiretroviral treat-
ment occurred in 5 recipients of placebo (5.0%) 
as compared with 20 recipients of a single dose of 
nevirapine (18.4%, P = 0.002) (Table 2 and Fig. 2A). 
Significantly higher rates of virologic failure were 
seen in recipients of a single dose of nevirapine 
as compared with recipients of a single dose of 
placebo at 12 months (P = 0.04) and 24 months 
(P = 0.008) after the initiation of antiretroviral 
treatment (Table 2 and Fig. 2A), and in the analy-
sis of time to virologic failure (P = 0.006).
The difference in outcomes depended on when 
antiretroviral treatment was initiated. In other 
words, for virologic failure there was an interac-
tion (P = 0.004) between exposure to a single dose 
of nevirapine or placebo and time to initiation of 
antiretroviral treatment. Among the 60 women 
starting antiretroviral treatment within 6 months 
after delivery, the estimated rates of virologic fail-
ure by the 6-month visit were 0 in the placebo 
group and 41.7% (10 women) in the nevirapine 
group (P<0.001) (Table 2 and Fig. 2C). Similar sig-
nificant differences were seen in the rates of viro-
logic failure at 12 and 24 months (Table 2 and 
Fig. 2C). However, among the 158 women who 
started antiretroviral treatment 6 months or more 
after delivery, there were no significant differences 
in rates of virologic failure or time to virologic fail-
ure between the women in the nevira pine group 
and those in the placebo group at 6, 12, or 24 
months after the initiation of antiretroviral treat-
ment (Table 2 and Fig. 2D). Similar results were 
observed when we compared suppression of HIV-1 
RNA levels to less than 400 copies per milliliter 
in the two groups of women at (rather than by) the 
visits at 6, 12, and 24 months after the initiation 
of antiretroviral treatment (data not shown).
Post hoc evaluation of our data suggested that 
it was logical to divide the women into subgroups 
according to a 6-month cutoff point for the time 
of initiation of antiretroviral treatment post par-
tum. When a 12-month cutoff point was used, the 
association between exposure to a single dose of 
nevirapine and virologic failure was somewhat 
attenuated (but still significant) in the women 
starting antiretroviral treatment less than 12 
months post partum (P<0.001 for all time points 
on antiretroviral treatment), with no significant 
differences in virologic failure among women 
starting 12 months or more post partum or among 
women starting between 6 and 12 months post 
partum (P≥0.30 for all comparisons).
There was a trend toward a higher rate of viro-
logic failure in the subgroup of placebo recipients 
who started antiretroviral treatment 6 months or 
more post partum than in the subgroup of pla-
cebo recipients who started antiretroviral treat-
ment less than 6 months post partum (P = 0.05). 
This trend was lessened after controlling for 
HIV-1 RNA levels before antiretroviral treatment 
(P = 0.11). These HIV-1 RNA levels were slightly 
higher in recipients of placebo who started anti-
retroviral treatment later post partum as com-
pared with earlier (5.2 log copies per milliliter 
vs. 5.0 log copies per milliliter, P = 0.05). Other 
characteristics, including CD4+ cell count, did not 
differ significantly between the two subgroups of 
placebo recipients. There were no significant dif-
ferences between such subgroups of nevirapine 
recipients other than the timing of the initiation 
of antiretroviral treatment. Initiation of antiretro-
viral treatment within 6 months post partum re-
mained significantly associated with virologic 
failure in nevirapine recipients, even after con-
trolling for HIV-1 RNA levels and CD4+ cell count 
(P = 0.004).
Ultrasensitive testing of plasma HIV-1 RNA was 
performed on all available samples from women 
who started antiretroviral treatment 6 months or 
more post partum and who had HIV-1 RNA levels 
of less than 400 copies per milliliter at 6 months 
of treatment; samples were available from 87 of 
Figure 1 (facing page). Women (Panel A) and Infants 
(Panel B) Enrolled in the Study.
All women in the Mashi trial received zidovudine from 
34 weeks’ gestation through delivery. Assignment of 
infants to receive a single dose of nevirapine or place-
bo reflected maternal assignments. ART denotes anti-
retroviral treatment, and NVP nevirapine.
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1200 Pregnant, HIV-positive women
enrolled in the Mashi trial
600 Randomly assigned
to peripartum placebo
600 Randomly assigned to a single,
peripartum dose of NVP
106 Started NVP-based ART
36 Started ART
<6 mo post partum
70 Started ART
 ≥6 mo post partum
24 Started ART
<6 mo post partum
88 Started ART
≥6 mo post partum
112 Started NVP-based ART
40 Started ART ante partum
2 Started non–NVP-based regimen
2 Started ART but were lost before
consent
31 Started ART ante partum
6 Started non–NVP-based regimen
5 Started ART but were lost before
consent
47 HIV-infected infants
25 Randomly assigned
to placebo
22 Randomly assigned to single
dose of NVP
15 Started ART 15 Started ART
5 Died before ART
2 Consent refused or lost to follow-up
7 Died before ART
3 Consent refused or lost to follow-up
11 of 12 Had HIV-1 RNA
measurements at 6 mo 
11 of 13 Had HIV-1 RNA
measurements at 6 mo 
2 Died3 Died
9 of 11 Had HIV-1 RNA
measurements at 12 mo 
10 of 13 Had HIV-1 RNA
measurements at 12 mo 
11 of 11 Had HIV-1 RNA
measurements at 24 mo 
9 of 9 Had HIV-1 RNA
measurements at 24 mo 
1 Lost to follow-up
3 Had not reached 24 mo
1 Had not reached 12 mo
34 of 36 Had HIV-1 RNA
measurements at 6 mo 
1 Died of tuberculosis
1 Lost to follow-up
62 of 68 Had HIV-1 RNA
measurements at 6 mo 
24 of 24 Had HIV-1 RNA
measurements at 6 mo 
1 Lost to follow-up
85 of 87 Had HIV-1 RNA
measurements at 6 mo 
35 of 36 Had HIV-1 RNA
measurements at 12 mo
5 Had not reached 12 mo
53 of 63 Had HIV-1 RNA
measurements at 12 mo
22 of 24 Had HIV-1 RNA
measurements at 12 mo
3 Had not reached 12 mo
72 of 84 Had HIV-1 RNA
measurements at 12 mo
5 Had not reached 24 mo
26 of 31 Had HIV-1 RNA
measurements at 24 mo 
32 Had not reached 24 mo
23 of 31 Had HIV-1 RNA
measurements at 24 mo 
3 Had not reached 24 mo
1 Off-study at 18 mo
19 of 20 Had HIV-1 RNA
measurements at 24 mo 
53 Had not reached 24 mo
28 of 31 Had HIV-1 RNA
measurements at 24 mo 
A Women
InfantsB
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143 women (60.8%) who met these criteria (36 in 
the placebo group and 51 in the group receiving 
a single dose of nevirapine). Of these 87 women, 
77.0% of those in the placebo group and 77.0% of 
those in the nevirapine group had HIV-1 RNA lev-
els of less than 50 copies per milliliter at 6 months, 
suggesting no notable differences between the 
end points of less than 50 copies per milliliter 
and less than 400 copies per milliliter.
The median change in the maternal CD4+ cell 
count at 6 months of antiretroviral treatment was 
an increase of 122 cells per cubic millimeter. 
There were no significant differences in the CD4+ 
cell count (level or change) between the group 
receiving a single dose of nevirapine and the pla-
cebo group, overall or within the timing sub-
groups — among women starting antiretroviral 
treatment within 6 months post partum, the me-
dian change in CD4+ cell count by the 6-month 
visit was an increase of 90 cells per cubic milli-
meter in the placebo group and an increase of 
101 cells per cubic millimeter in the nevirapine 
group (P = 0.86).
In univariate analyses of time to virologic fail-
ure, pre–antiretroviral-treatment HIV-1 RNA levels, 
CD4+ cell count, and status of exposure to nevir-
apine (whether a woman received placebo or a 
single dose of nevirapine) were significantly asso-
ciated with virologic failure (Table 3); assigned 
feeding strategy, maternal age, and study clinic 
Table 1. Maternal and Infant Characteristics According to Peripartum Treatment Group.*
Maternal Characteristic
Placebo Group 
(N = 106)
Group Receiving a Single 
Dose of Nevirapine
(N = 112) P Value
Age at enrollment in Mashi trial — yr
Median 27.5 27.5 0.64
Interquartile range 24.2–32.3 24.2–32.4
Randomly assigned to breast-feeding — no. (%) 52 (49.1)  55 (49.1) 0.99
Self-reported ingestion of placebo or single dose of NVP 
during labor — no. (%)
98 (92.5) 106 (94.6) 0.51
CD4+ count at enrollment (ante partum) — cells/mm3
Median 204 205 0.51
Interquartile range 140–296 137–267
CD4+ count before ART
Median — cells/mm3 168 164 0.49
Interquartile range — cells/mm3 112–198 100–195
<50 cells/mm3 —no. of women (%) 6 (5.7) 9 (8.0)
Plasma HIV-1 RNA level at enrollment (ante partum) 
— log copies/ml
Median 5.0 5.0 0.87
Interquartile range 4.5–5.3 4.5–5.4
Plasma HIV-1 RNA level before ART — log copies/ml
Median 5.2 5.1 0.87
Interquartile range 4.7–5.6 4.7–5.7
Time to initiation of ART after delivery 
Median — mo 10.1 12.3 0.58
Within 6 mo after exposure to a single dose of NVP 
or placebo — no. (%)
36 (34.0)  24 (21.4)
Criteria for initiation of ART — no. (%)
CD4+ count <200 cells/mm3 98 (92.5) 104 (92.9) 0.81
AIDS-defining illness 2 (1.9)  1 (0.9)
Both 6 (5.7)  7 (6.3)
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were not. In a multivariate model stratified ac-
cording to the timing of the initiation of antiretro-
viral treatment, pre–antiretroviral-treatment CD4+ 
cell count (but not plasma HIV-1 RNA level) and 
receipt of a single dose of nevirapine remained 
significantly associated with time to virologic 
failure (Table 3).
When virologic failure was examined among 
only the 111 women who entered the Mashi trial 
with an antepartum CD4+ count of 200 cells or 
more per cubic millimeter, no significant differ-
ence was observed in rates of virologic failure be-
tween women who received a single dose of nevi-
rapine and those who received placebo (with most 
of these women starting antiretroviral treatment 
6 months or more post partum).
Maternal Genotype Results
Plasma samples from 16 of 20 women who received 
a single dose of nevirapine and who had viro-
logic failure by 6 months of antiretroviral treat-
ment were tested for HIV-1 resistance mutations 
before the start of antiretroviral treatment and at 
the time of virologic failure. Of these women, 
three (18.8%) had no detectable nevirapine resis-
tance mutations before antiretroviral treatment 
or at the time of virologic failure, one (6.2%) had 
resistance at baseline but not at the time of fail-
ure, five (31.2%) had no resistance at baseline but 
had resistance at the time of failure, and seven 
(43.8%) had resistance both at baseline and at the 
time of failure. All 16 women were infected with 
HIV-1 subtype C (phylogenetic analysis of 368 
Table 1. (Continued.)
Infant Characteristic
Placebo Group
(N = 15)
Group Receiving a Single 
Dose of Nevirapine
(N = 15) P Value
Age at diagnosis of HIV-1
Median — mo 1.0 0.9 0.95
HIV-positive at birth — no. (%)  7 (46.7)  8 (53.3)
HIV-positive at ≥6 mo of age — no. (%)  2 (13.3)  3 (20.0)
Randomly assigned to breast-feeding — no. (%) 10 (66.7) 13 (86.7) 0.39
CD4+ cell count before ART
Median — % 23.5 18.0 0.53
Missing CD4+ cell count — no. (%)  7 (46.7)  4 (26.7)
Plasma HIV-1 RNA level before ART
Median — log copies/ml 5.9 5.9 0.48
<5.0 log copies/ml — no. (%)  2 (13.3) 0 
Missing plasma HIV-1 RNA level — no. (%)  3 (20.0)  4 (26.7)
Duration of zidovudine prophylaxis before 
starting ART
Median — mo 1.1 2.0 0.68
<1 mo — no. (%)  5 (33.3)  3 (20.0)
1 to <3 mo — no. (%)  4 (26.7)  6 (40.0)
3 to 6 mo — no. (%)  6 (40.0)  6 (40.0)
Age at initiation of ART 
Median — mo 8.38 8.51 0.95
Range — mo 3.5–32.8 2.1–33.4
<6 mo — no. (%)  3 (20.0)  5 (33.3)
6 to <12 mo — no. (%)  7 (46.7)  5 (33.3)
12 to <18 mo — no. (%)  3 (20.0)  3 (20.0)
≥18 mo — no. (%)  2 (13.3)  2 (13.3)
* NVP denotes nevirapine, and ART antiretroviral treatment.
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maternal HIV-1 sequences in the Mashi trial re-
vealed that all but 1 belonged to HIV-1C).
Nevirapine-based antiretroviral treatment 
in Infants
Thirty infants born before August 12, 2002, start-
ed nevirapine-based antiretroviral treatment; 15 
had received placebo and 15 had received a single 
dose of nevirapine (Fig. 1B). Baseline character-
istics were similar in the two groups (Table 1). 
Three infants who had received placebo and two 
who had received a single dose of nevirapine died 
after initiation of antiretroviral treatment but be-
fore the 6-month visit; therefore, none of the five 
met the primary end point of virologic failure. By 
6 months after the initiation of antiretroviral treat-
ment, 1 infant in the placebo group (9.1%) and 10 
in the group receiving a single dose of nevirapine 
(76.9%) had virologic failure (P<0.001) (Table 2 
and Fig. 2B).
The distribution of and changes in the CD4+ 
percentages after the initiation of antiretroviral 
treatment in infants were significantly lower at 
most time points in infants who had received a 
single dose of nevirapine than in those who had 
received placebo. At 6 months after the initiation 
of antiretroviral treatment, the median CD4+ per-
centages were 23.0% in infants who had received 
a single dose of nevirapine and 31.0% in those 
who had received placebo (P = 0.04), with median 
increases in CD4+ cells of 5.8 percentage points 
and 13.0 percentage points, respectively (P = 0.30). 
The median CD4+ percentages at 12 months after 
the initiation of antiretroviral treatment were 
Table 2. Virologic Failure in Women and Infants by 6 Months after Initiation of Antiretroviral Treatment (ART).*
Variable Placebo Group
Group Receiving 
a Single Dose 
of Nevirapine P Value
All women N = 106 N = 112
no. (%)
Mo after initiation of ART
6 5 (5.0) 20 (18.4) 0.002
12 9 (9.6) 21 (19.7) 0.04
24 10 (11.3) 25 (27.9) 0.008
Women who started ART <6 mo after delivery N = 36 N = 24
no. (%)
Mo after initiation of ART
6 0 10 (41.7) <0.001
12 1 (2.9) 11 (45.8) <0.001
24 1 (2.9) 11 (45.8) <0.001
Women who started ART ≥6 mo after delivery N = 70 N = 88
no. (%)
Mo after initiation of ART
6 5 (7.8) 10 (12.0) 0.39
12 8 (13.8) 10 (12.0) 0.76
24 9 (17.1) 14 (24.7) 0.38
All infants N = 15 N = 15
no. (%)
Mo after initiation of ART
6 1 (9.1) 10 (76.9) <0.001
12 1 (9.1) 10 (76.9) <0.001
24 2 (18.2) 10 (76.9) <0.001
* Rates of virologic failure were estimated with the use of Kaplan–Meier analyses.
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28.6% (5.2% increase) in the group receiving a 
single dose of nevirapine and 37.1% (22.0% in-
crease) in the placebo group (P = 0.01 for both 
comparisons).
Discussion
Women who had received a single dose of nevi-
rapine had significantly higher rates of virologic 
failure on subsequent nevirapine-based antiretro-
viral treatment than did women who had received 
placebo. This apparently deleterious effect of a 
single dose of nevirapine was concentrated in 
women who initiated antiretroviral treatment 
within 6 months after receiving a single dose of 
nevirapine. We did not find that a previous single 
dose of nevirapine compromised the efficacy of 
subsequent nevirapine-based antiretroviral treat-
ment in women who started antiretroviral treat-
ment 6 months or more after delivery. Among the 
30 HIV-infected infants, a single dose of nevira-
pine (one each to mother and infant) as compared 
with placebo was associated with significantly 
higher rates of virologic failure and smaller CD4+ 
percentage increases in response to subsequent 
nevirapine-based antiretroviral treatment.
These data suggest that women who start nevir-
apine-based antiretroviral treatment later after 
receiving a single dose of nevirapine may have 
rates of virologic suppression as high as those 
among women who have not previously received 
a single dose of nevirapine. Jourdain et al. did not 
find that rates of virologic failure varied accord-
ing to the timing of the initiation of antiretro-
viral treatment after a single dose of nevirapine.14 
However, the ability of the Thai study to detect 
interaction between exposure to a single dose of 
nevirapine and the timing of antiretroviral-treat-
ment initiation was limited, because only 48 
women did not receive a single dose of nevira-
pine (and this group started antiretroviral treat-
ment significantly later than the women who 
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Figure 2. Time to Virologic Failure.
ART denotes antiretroviral treatment, and NVP nevirapine.
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received a single dose of nevirapine).14 Recent ab-
stracts also suggest that virologic17 and immuno-
logic18 outcomes of nevirapine-based antiretro-
viral treatment in a program setting are similar 
in women who received a single dose of nevirap-
ine 9 months or more previously and in those who 
did not receive a single dose of nevirapine. How-
ever, these studies enrolled nevi rapine-exposed 
and nevirapine-unexposed women with confound-
ing differences in key prognostic factors — im-
portant limiting biases that are likely to affect 
any study enrolling women who have not been 
contemporaneously randomly assigned to receive 
or not receive a single peripartum dose of nevi-
rapine.
Our finding that virologic failure after expo-
Table 3. Predictors of Virologic Failure in Women.*
Factor
Univariate
Hazard Ratio (95% CI)†
Multivariate 
Hazard Ratio (95% CI)‡
All women
HIV RNA level before ART
Per 1 log increase 1.9 (1.0–3.4) 1.9 (1.0–3.9)
≥5.0 log copies/ml versus <5.0 log copies/ml 1.6 (0.8–3.3) 1.8 (0.9–3.8)
CD4+ count before ART
Per increase of 10 cells/mm3 0.9 (0.9–1.0) 0.9 (0.9–1.0)
<200 cells/mm3 versus ≥200 cells/mm3 2.5 (0.8–8.2) 2.9 (0.9–9.4)
Single-dose NVP versus placebo 2.7 (1.3–5.8)
Controlling for continuous covariates 4.9 (1.8–13.3)
Controlling for covariate subgroups 2.9 (1.4–6.3)
Women starting ART <6 mo post partum
HIV RNA level before ART
Per 1 log increase 2.6 (0.9–7.1) 4.3 (1.1–16.8)
≥5.0 log copies/ml versus <5.0 log copies/ml 4.4 (1.0–20.1) 6.3 (1.3–29.1)
CD4+ count before ART
Per increase of 10 cells/mm3 0.8 (0.5–1.2) 0.95 (0.9–1.0)
<200 cells/mm3 versus ≥200 cells/mm3 3.4 (0.4–26.7) 5.5 (0.7–43.1)
Single-dose NVP versus placebo 22 (2.8–169.0)
Controlling for continuous covariates Large, unstable
Controlling for covariate subgroups 27.9 (3.5–219.0)
Women starting ART ≥6 mo post partum
HIV RNA level before ART
Per 1 log increase 1.5 (0.7–3.2) 1.3 (0.6–3.0)
≥5.0 log copies/ml versus <5.0 log copies/ml 1.0 (0.4–2.4) 1.0 (0.4–2.5)
CD4+ count before ART
Per increase of 10 cells/mm3 0.9 (0.9–1.0) 0.9 (0.9–1.0)
<200 cells/mm3 versus ≥200 cells/mm3 2.1 (0.5–9.0) 2.1 (0.5–2.7)
Single-dose NVP versus placebo 1.2 (0.5–2.8)
Controlling for continuous covariates 1.9 (0.7–5.4)
Controlling for covariate subgroups 1.2 (0.5–2.8)
* CI denotes confidence interval, ART antiretroviral therapy, and NVP nevirapine.
† The following factors were not associated with time to virologic failure in univariate analyses: study site (P = 0.66), 
maternal age (P = 0.84), assigned infant-feeding strategy (P = 0.54), and plasma HIV-1 RNA level at enrollment (P = 0.09).
‡ The multivariate hazard ratios were adjusted for HIV RNA levels before ART, CD4+ cell count before ART, and receipt 
of a single dose of nevirapine or placebo.
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sure to a single dose of nevirapine is more likely 
to occur when postpartum antiretroviral treat-
ment is started earlier, as opposed to later, is 
consistent with the observation that nevirapine 
resistance mutations fade from detection with 
time, although mutant strains are still detectable 
in some women and infants 12 to 24 months af-
ter exposure to a single dose of nevirapine when 
highly sensitive resistance assays are used.19-21 
Mutations archived after exposure to a single 
dose of nevirapine may reemerge with a longer 
duration of nevirapine-based antiretroviral treat-
ment. However, the short duration of exposure 
to a single dose of nevirapine may limit the num-
ber of archived mutations in viral reservoirs. 
Minor nevirapine-resistant variants archived in 
cellular DNA were found to decline from 52% at 
6 weeks to 4% at 12 months post partum in one 
South African study.19 Additional follow-up from 
the Thai study14 showed that among women with 
virologic suppression after 6 months of antiretro-
viral treatment who received a single dose of 
nevirapine or placebo, no differences in treatment 
response emerged with follow-up through 18 
months.22 We are continuing to follow (and enroll 
participants in) the Mashi cohort of women who 
are receiving antiretroviral treatment, to evaluate 
the longevity of virologic suppression in a larger 
number of recipients of a single dose of nevirapine 
or placebo who started antiretroviral treatment 
6 months or more post partum. This additional 
follow-up is important, since data on 24-month 
HIV-1 RNA levels were available for only 96 
women.
We found trends toward higher rates of viro-
logic failure and higher pretreatment HIV-1 RNA 
levels in placebo-exposed women who started 
antiretroviral treatment later, as compared with 
earlier, post partum; some women starting treat-
ment 6 months or more post partum may have 
had progression to more advanced HIV disease by 
the time antiretroviral treatment became avail-
able. However, because women who had received 
a single dose of nevirapine or placebo started anti-
retroviral treatment at similar times post partum 
and at similar disease stages, temporal differences 
should apply in a similar way to both women who 
had received a single dose of nevirapine and those 
who had received placebo.
The difference in treatment response among 
infants was large. However, this was a very small 
group that started antiretroviral treatment at a 
relatively young age and that also received perina-
tal zidovudine. Although our findings raise con-
cern about the efficacy of nevirapine-based anti-
retroviral treatment in infants receiving a single 
dose of nevirapine, pediatric data from other stud-
ies will be very important.
Rates of detectable nevirapine resistance mu-
tations seem to be higher in women and infants 
when a single dose of nevirapine is the only drug 
used for the prevention of mother-to-child trans-
mission of HIV-113,23,24; it is possible that differ-
ences in treatment outcome may be worse after 
exposure to only a single dose of nevirapine (as 
compared with exposure to a single dose of ne-
virapine and zidovudine, as in this study). A regi-
men of a short course of zidovudine plus a single 
dose of nevirapine (similar to the Mashi trial 
regimen) is now used to prevent mother-to-child 
transmission of HIV-1 in many developing na-
tions, in accordance with WHO guidelines.1
HIV-1 subtype C is the most prevalent HIV-1 
subtype globally,25 predominating in southern 
Africa (including Botswana) and much of Asia 
and accounting for 99.7% of tested HIV-1 isolates 
from participants in the Mashi trial. Nevirapine 
resistance mutations after a single dose of ne-
virapine may emerge more frequently with HIV-1 
subtype C than with other HIV-1 subtypes.9,26 
Therefore, women with non-C subtypes who start 
antiretroviral treatment 6 months or more after 
receiving a single dose of nevirapine may have 
therapeutic outcomes that are at least as favorable 
as those observed in this study. Although our 
results are quite broadly applicable, data from 
populations infected with other HIV-1 subtypes 
or data resulting from the use of other regimens 
containing a single dose of nevirapine for the 
prevention of mother-to-child transmission of 
HIV-1 would provide additional insights. 
In summary, this study shows that women 
who start nevirapine-based antiretroviral treat-
ment 6 months or more after receiving a single 
dose of nevirapine have rates of virologic sup-
pression similar to those among women who are 
not exposed to nevirapine, and that nevirapine-
based treatment may therefore be considered for 
such women. However, it will be important to 
evaluate virologic responses after at least 24 
months of follow-up of this cohort. Because it 
may not be safe to de lay the initiation of anti-
retroviral treatment for 6 months or more post 
partum in women with advanced AIDS, initiation 
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of non–nevirapine-based regimens should be con-
sidered for women starting antiretroviral treat-
ment within 6 months after receiving a single 
dose of nevirapine. Furthermore, exposure to a 
single dose of nevirapine followed by nevirapine-
based antiretroviral treatment was associated 
with high rates of virologic failure in the small 
group of infants that we studied.
Every effort should be made to provide ante-
partum combination antiretroviral treatment to 
women who qualify for antiretroviral treatment 
for their own health, since these are the women 
at highest risk for AIDS-related complications or 
death, for transmitting HIV to their infants, and 
for the development of nevirapine resistance af-
ter a single dose of nevirapine. However, single-
dose nevirapine (with or without additional anti-
retroviral agents) remains an important component 
of the global strategy for the prevention of moth-
er-to-child transmission of HIV-1 in women who 
do not yet qualify for antiretroviral treatment and 
for areas where treatment is not available. Our 
finding that women with more remote exposure 
to a single dose of nevirapine have high rates of 
virologic suppression in response to nevirapine-
based antiretroviral treatment is reassuring for 
the many women who have received a single dose 
of nevirapine and to those who will receive it.
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